Related Experiment Video
Updated: Jun 14, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro
Kai Lin1, Sylwia Karwowska, Eric Lam
1Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139, USA. kai.lin@novartis.com
Abstract:
Most approved drugs with activity against hepatitis B virus (HBV) have activity against human immunodeficiency virus type 1 (HIV-1), which precludes their use in patients who are coinfected with HBV and HIV-1 and who are not receiving antiretroviral therapy due to the risk of inducing resistance. The activity of telbivudine, a highly selective HBV inhibitor, against temporally and geographically distinct wild-type and multidrug-resistant HIV-1 clinical isolates was evaluated in vitro. No inhibition was observed with up to 600 muM drug, which supports further exploration of telbivudine as a therapeutic option for the treatment of HBV infections in patients coinfected with HIV-1.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Inhibitors Of Virion Release
Inhibitors of Virion Maturation and Assembly
Antiviral Nucleoside Inhibitors
Inhibitors of Bacterial DNA Synthesis
Retrovirus Life Cycles

